| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8658807 | Diabetes & Metabolic Syndrome: Clinical Research & Reviews | 2018 | 5 Pages |
Abstract
We observed that a considerable proportion of patients with type 2 diabetes and CKD were receiving metformin and non dose-adjusted DPP-4 inhibitors. Careful consideration of medication use and dosaging is required in the setting of CKD and type 2 diabetes.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Thinzar Min, Gareth I. Davies, Sam Rice, James Chess, Jeffrey W. Stephens,